Secondary responder analysis of an RCT in 517 patients with symptomatic nonobstructive HCM: at 36 weeks, 53% on aficamten vs 14% on placebo improved on ≥3 of 5 measures (P<0.001). Symptoms, LA volume, e' and NT-proBNP improved; peak VO2 did not (45% vs 37%, P=0.1).
RCTn = 517
Maron et al. Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM